A new generation of drugs and drug combinations is changing the outlook for patients with endometrial cancer. The results of the first clinical trials of the new therapies were so promising that they’ve led researchers to launch follow-up trials to explore the potential for even better outcomes. The trials are geared to patients diagnosed with … Read more
Dana-Farber scientists presented an abundance of new research at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 1-4 in San Diego. Their research spanned the gamut of hematological diseases, including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome—as well as treatment modalities, such as stem cell transplantation and CAR T-cell therapy. A … Read more
This post originally appeared on Vector, Boston Children’s Hospital’s blog. Our blood carries tiny amounts of DNA from broken-up cells. If we have cancer, some of that DNA comes from tumor cells. Studies performed with adult cancers have shown that this circulating tumor DNA (ctDNA) may offer crucial clues about tumor genetic mutations and how … Read more
In recounting her odyssey from Slovakian high school exchange student to Dana-Farber principal investigator, Zuzana Tothova, MD, PhD, often says modestly, “I was very lucky.” Perhaps. But it’s also true that, at pivotal points in her journey, Tothova was recognized as a person of exceptional promise, with mentors encouraging her and taking extra steps to … Read more
It may not be sporting to hit someone when they’re down, but when the foe is a cancer cell, there’s no merit in mercy. That’s the principle behind drugs known as PARP inhibitors. Tumor cells that lack effective BRCA genes have difficulty repairing certain kinds of DNA damage, potentially leaving them vulnerable to agents that … Read more
Thalidomide, a morning-sickness drug recalled in the 1960s because it caused devastating birth defects, is now commonly used to treat multiple myeloma and other blood cancers. It and its chemical relatives work by causing cells to destroy two proteins — members of a larger family of conventionally “undruggable” proteins called transcription factors — that feature … Read more
Desolate as a man stranded on a desert isle may be, he can at least be certain that, barring a tsunami, his refuge won’t crumble into the sea. The castaway chromosomes of cancer cells lack even that degree of assurance. Unlike the chromosomes in normal cells, the chromosomes in some cancer cells aren’t always neatly … Read more
Tests on living “organoids” created from patients’ ovarian cancer cells proved more accurate than DNA sequencing in predicting tumors’ sensitivity or resistance to chemotherapy drugs – and combining the two methods worked even better, say scientists at Dana-Farber Cancer Institute. The investigators report in Cancer Discovery that ovarian cancer organoids – tiny, three-dimensional spheres of cells … Read more
The most commonly mutated gene in cancer has tantalized scientists for decades with the message of its mutations. Although mutations can occur at more than 1,100 sites within the TP53 gene, they arise with greatest frequency at a handful of points dubbed “hot spots.” Does this imbalance suggest that hotspot mutations are especially conducive to … Read more
From new immunotherapy treatments to improved understanding of the genetic mechanisms of pediatric tumors, the past year has brought many important advances against childhood cancers. We sat down with Scott Armstrong, MD, PhD, chair of Pediatric Oncology at Dana-Farber Cancer Institute, to discuss some of these developments. CAR T-Cell Therapy for Relapsed ALL A CAR … Read more
A study by Dana-Farber scientists and an international team of researchers could lead to better treatments for patients with smoldering multiple myeloma, a condition that often precedes myeloma.
Scientists at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.
A recent discovery about prostate cancer suggests potential new targeted therapeutic strategies for this disease.
In a significant step toward more personalized treatment for patients with breast cancer, a recent clinical trial found that many women with an early stage of the disease do not need chemotherapy after surgery to remove the tumor.
Cancer biologists led by Cigall Kadoch, PhD, of Dana-Farber Cancer Institute, have identified a key molecular event that leads to synovial sarcoma, a rare, aggressive cancer in adolescents and young adults for which scientists are seeking better treatments.
Scientists at Dana-Farber and other institutions have shown that compounds that mimic key proteins on white blood cells can inactivate HIV-1, the virus that causes AIDS, and potentially protect against exposure to the virus.
Researchers are applying the knowledge they’ve gained in previous clinical trials as they look into how immunotherapy might provide additional treatment options for patients with recurrent cervical cancer.
So far, CDK4/6 inhibitors have been shown to be most effective in treating advanced estrogen-receptor positive, HER2-negative breast cancer.
As scientists map ever more of the epigenetic disruptions that occur in cancer, the implications for cancer therapy are becoming increasingly evident.
This originally appeared on Vector, Boston Children’s Hospital’s blog. A novel screening method using CRISPR-Cas9 genome editing technology has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy. The method, developed by a team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, uses … Read more